Potential Prognostic Predictors and Molecular Targets for Skin Melanoma Screened by Weighted Gene Co-expression Network Analysis

Author(s): Sichao Chen, Zeming Liu, Man Li, Yihui Huang, Min Wang, Wen Zeng, Wei Wei, Chao Zhang, Yan Gong*, Liang Guo*

Journal Name: Current Gene Therapy

Volume 20 , Issue 1 , 2020


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Aims and Objectives: Among skin cancers, malignant skin melanoma is the leading cause of death. Identification of gene markers of malignant skin melanoma associated with survival may provide new clues for prognosis prediction and treatment. This research aimed to screen out potential prognostic predictors and molecular targets for malignant skin melanoma.

Introduction: Information regarding gene expression in skin melanoma and patients’ clinical traits was obtained from the Gene Expression Omnibus database. Weighted gene co-expression network analysis (WGCNA) was applied to build co-expression modules and investigate the association between the modules and clinical traits. Moreover, functional enrichment analysis was performed for clinically significant co-expression modules. Hub genes of these modules were validated via Gene Expression Profiling Interactive Analysis (GEPIA) and the Human Protein Atlas (http:// www.proteinatlas.org).

Methods: First, using WGCNA, 9 co-expression modules were constructed by the top 25% differentially expressed genes (4406 genes) from 77 human melanoma samples. Two co-expression modules (magenta and blue modules) were significantly correlated with survival months (r = -0.27, p = 0.02; r = 0.27, p = 0.02, respectively). The results of functional enrichment analysis demonstrated that the magenta module was mainly enriched in the cell cycle process and the blue module was mainly enriched in the immune response process. Additionally, the GEPIA and Human Protein Atlas results suggested that the hub genes CCNB2, ARHGAP30, and SEMA4D were associated with relapse-free survival and overall survival (all p-values < 0.05) and were differentially expressed in melanoma tumors and normal skin.

Results and Conclusion: The results provided the framework of co-expression gene modules of skin melanoma and screened out CCNB2, ARHGAP30, and SEMA4D associated with survival as potential prognostic predictors and molecular targets of treatment.

Keywords: Melanoma, WGCNA, prognosis, CCNB2, ARHGAP30, SEMA4D.

[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69(1): 7-34.
[http://dx.doi.org/10.3322/caac.21551] [PMID: 30620402]
[2]
Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2013. Bethesda, MD: National Cancer Institute 2016.
[3]
Shao C, Dai W, Li H, et al. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics. PLoS One 2017; 12(2): e0171676
[http://dx.doi.org/10.1371/journal.pone.0171676] [PMID: 28207831]
[4]
Barut F, Udul P, Kokturk F, Kandemir NO, Keser SH, Ozdamar SO. Clinicopathological features and pituitary homeobox 1 gene expression in the progression and prognosis of cutaneous malignant melanoma. Kaohsiung J Med Sci 2016; 32(10): 494-500.
[http://dx.doi.org/10.1016/j.kjms.2016.08.001] [PMID: 27742032]
[5]
Liu H, Zhou M. Evaluation of p53 gene expression and prognosis characteristics in uveal melanoma cases. OncoTargets Ther 2017; 10: 3429-34.
[http://dx.doi.org/10.2147/OTT.S136785] [PMID: 28744147]
[6]
Yan J, Yu J, Wu X, et al. Increased AURKA gene copy number correlates with poor prognosis and predicts the efficacy of High-dose interferon therapy in acral melanoma. J Cancer 2018; 9(7): 1267-76.
[http://dx.doi.org/10.7150/jca.24013] [PMID: 29675108]
[7]
Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 2015; 21(1): 175-83.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-3316]
[8]
Uhara H. Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. Int J Clin Oncol 2019; 24(12): 1508-14.
[PMID: 29470725]
[9]
Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019; 381(7): 626-36.
[http://dx.doi.org/10.1056/NEJMoa1904059] [PMID: 31166680]
[10]
Guo Y, Ma J, Xiao L, et al. Identification of key pathways and genes in different types of chronic kidney disease based on WGCNA. Mol Med Rep 2019; 20(3): 2245-57.
[http://dx.doi.org/10.3892/mmr.2019.10443] [PMID: 31257514]
[11]
Xia WX, Yu Q, Li GH, et al. Identification of four hub genes associated with adrenocortical carcinoma progression by WGCNA. PeerJ 2019; 7: e6555
[http://dx.doi.org/10.7717/peerj.6555] [PMID: 30886771]
[12]
Di Y, Chen D, Yu W, Yan L. Bladder cancer stage-associated hub genes revealed by WGCNA co-expression network analysis. Hereditas 2019; 156: 7.
[http://dx.doi.org/10.1186/s41065-019-0083-y] [PMID: 30723390]
[13]
Mann GJ, Pupo GM, Campain AE, et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 2013; 133(2): 509-17.
[http://dx.doi.org/10.1038/jid.2012.283] [PMID: 22931913]
[14]
Mason MJ, Fan G, Plath K, Zhou Q, Horvath S. Signed weighted gene co-expression network analysis of transcriptional regulation in murine embryonic stem cells. BMC Genomics 2009; 10(1): 327.
[http://dx.doi.org/10.1186/1471-2164-10-327] [PMID: 19619308]
[15]
Yip AM, Horvath S. Gene network interconnectedness and the generalized topological overlap measure. BMC Bioinformatics 2007; 8: 22.
[http://dx.doi.org/10.1186/1471-2105-8-22] [PMID: 17250769]
[16]
Langfelder P, Horvath S. Eigengene networks for studying the relationships between co-expression modules. BMC Syst Biol 2007; 1: 54.
[http://dx.doi.org/10.1186/1752-0509-1-54] [PMID: 18031580]
[17]
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017; 45(W1): W98-W102.
[http://dx.doi.org/10.1093/nar/gkx247] [PMID: 28407145]
[18]
Takashima S, Saito H, Takahashi N, et al. Strong expression of cyclin B2 mRNA correlates with a poor prognosis in patients with non-small cell lung cancer. Tumour Biol 2014; 35(5): 4257-65.
[http://dx.doi.org/10.1007/s13277-013-1556-7] [PMID: 24375198]
[19]
Li R, Jiang X, Zhang Y, et al. Cyclin B2 overexpression in human hepatocellular carcinoma is associated with poor prognosis. Arch Med Res 2019; 50(1): 10-7.
[http://dx.doi.org/10.1016/j.arcmed.2019.03.003] [PMID: 31101236]
[20]
Shubbar E, Kovács A, Hajizadeh S, et al. Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer 2013; 13: 1.
[http://dx.doi.org/10.1186/1471-2407-13-1] [PMID: 23282137]
[21]
Shi Q, Wang W, Jia Z, Chen P, Ma K, Zhou C. ISL1, a novel regulator of CCNB1, CCNB2 and c-MYC genes, promotes gastric cancer cell proliferation and tumor growth. Oncotarget 2016; 7(24): 36489-500.
[http://dx.doi.org/10.18632/oncotarget.9269] [PMID: 27183908]
[22]
Naji L, Pacholsky D, Aspenström P. ARHGAP30 is a Wrch-1-interacting protein involved in actin dynamics and cell adhesion. Biochem Biophys Res Commun 2011; 409(1): 96-102.
[http://dx.doi.org/10.1016/j.bbrc.2011.04.116] [PMID: 21565175]
[23]
Wang J, Qian J, Hu Y, et al. ArhGAP30 promotes p53 acetylation and function in colorectal cancer. Nat Commun 2014; 5: 4735.
[http://dx.doi.org/10.1038/ncomms5735] [PMID: 25156493]
[24]
Mao X, Tong J. ARHGAP30 suppressed lung cancer cell proliferation, migration, and invasion through inhibition of the Wnt/β-catenin signaling pathway. OncoTargets Ther 2018; 11: 7447-57.
[http://dx.doi.org/10.2147/OTT.S175255] [PMID: 30425532]
[25]
Li H, Wang JS, Mu LJ, Shan KS, Li LP, Zhou YB. Promotion of Sema4D expression by tumor-associated macrophages: Significance in gastric carcinoma. World J Gastroenterol 2018; 24(5): 593-601.
[http://dx.doi.org/10.3748/wjg.v24.i5.593] [PMID: 29434448]
[26]
Xia Y, Cai XY, Fan JQ, et al. The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms. Int J Cancer 2019; 144(9): 2227-38.
[http://dx.doi.org/10.1002/ijc.31958] [PMID: 30374974]
[27]
Chen Y, Zhang L, Liu WX, Wang K. VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer. Cell Mol Biol Lett 2018; 23: 2.
[http://dx.doi.org/10.1186/s11658-017-0058-9] [PMID: 29308068]
[28]
Soong J, Scott G. Plexin B1 inhibits MET through direct association and regulates Shp2 expression in melanocytes. J Cell Sci 2013; 126(Pt 2): 688-95.
[http://dx.doi.org/10.1242/jcs.119487] [PMID: 23203808]
[29]
Soong J, Chen Y, Shustef EM, Scott GA. Sema4D, the ligand for Plexin B1, suppresses c-Met activation and migration and promotes melanocyte survival and growth. J Invest Dermatol 2012; 132(4): 1230-8.
[http://dx.doi.org/10.1038/jid.2011.414] [PMID: 22189792]
[30]
Heo JR, Kim NH, Cho J, Choi KC. Current treatments for advanced melanoma and introduction of a promising novel gene therapy for melanoma (Review). Oncol Rep 2016; 36(4): 1779-86.
[http://dx.doi.org/10.3892/or.2016.5032] [PMID: 27573048]
[31]
Menezes ME, Talukdar S, Wechman SL, et al. Prospects of gene therapy to treat melanoma. Adv Cancer Res 2018; 138: 213-37.
[http://dx.doi.org/10.1016/bs.acr.2018.02.007] [PMID: 29551128]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 1
Year: 2020
Published on: 23 June, 2020
Page: [5 - 14]
Pages: 10
DOI: 10.2174/1566523220666200516170832
Price: $65

Article Metrics

PDF: 23
HTML: 2